Literature DB >> 10834992

Molecular characterization of Campylobacter jejuni from patients with Guillain-Barré and Miller Fisher syndromes.

H P Endtz1, C W Ang, N van Den Braak, B Duim, A Rigter, L J Price, D L Woodward, F G Rodgers, W M Johnson, J A Wagenaar, B C Jacobs, H A Verbrugh, A van Belkum.   

Abstract

Campylobacter jejuni has been identified as the predominant cause of antecedent infection in Guillain-Barré syndrome (GBS) and Miller Fisher syndrome (MFS). The risk of developing GBS or MFS may be higher after infection with specific C. jejuni types. To investigate the putative clonality, 18 GBS- or MFS-related C. jejuni strains from The Netherlands and Belgium and 17 control strains were analyzed by serotyping (Penner and Lior), restriction fragment length polymorphism analysis of PCR products of the flaA gene, amplified fragment length polymorphism analysis, pulsed-field gel electrophoresis, and randomly amplified polymorphic DNA analysis. Serotyping revealed 10 different O serotypes and 7 different Lior serotypes, thereby indicating a lack of serotype clustering. Two new O serotypes, O:35 and O:13/65, not previously associated with GBS or MFS were found. Serotype O:19 was encountered in 2 of 18 strains, and none was of serotype O:41. The results of all genotypic methods also demonstrated substantial heterogeneity. No clustering of GBS- or MFS-related strains occurred and no molecular marker capable of separating pathogenic GBS or MFS from non-GBS- or non-MFS-related enteritis strains could be identified in this study. Sialic-acid-containing lipopolysaccharides (LPS) are thought to be involved in the triggering of GBS or MFS through molecular mimicry with gangliosides in human peripheral nerves. Therefore, further characterization of GBS- or MFS-related C. jejuni should target the genes involved in the synthesis of LPS and the incorporation of sialic acid.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10834992      PMCID: PMC86786          DOI: 10.1128/JCM.38.6.2297-2301.2000

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  30 in total

Review 1.  Assessment of current diagnostic criteria for Guillain-Barré syndrome.

Authors:  A K Asbury; D R Cornblath
Journal:  Ann Neurol       Date:  1990       Impact factor: 10.422

Review 2.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

3.  Genotypic diversity of Campylobacter lari isolated from mussels and oysters in The Netherlands.

Authors:  H P Endtz; J S Vliegenthart; P Vandamme; H W Weverink; N P van den Braak; H A Verbrugh; A van Belkum
Journal:  Int J Food Microbiol       Date:  1997-01       Impact factor: 5.277

4.  Guillain-Barré syndrome in South Africa associated with Campylobacter jejuni O:41 strains.

Authors:  A J Lastovica; E A Goddard; A C Argent
Journal:  J Infect Dis       Date:  1997-12       Impact factor: 5.226

Review 5.  Structure and conserved characteristics of Campylobacter jejuni lipopolysaccharides.

Authors:  A P Moran
Journal:  J Infect Dis       Date:  1997-12       Impact factor: 5.226

6.  Restriction fragment length polymorphism analysis and random amplified polymorphic DNA analysis of Campylobacter jejuni strains isolated from patients with Guillain-Barré syndrome.

Authors:  S Fujimoto; B M Allos; N Misawa; C M Patton; M J Blaser
Journal:  J Infect Dis       Date:  1997-10       Impact factor: 5.226

7.  Serotyping of and hippurate hydrolysis by Campylobacter jejuni isolates from human patients, poultry and pigs in the Netherlands.

Authors:  J Oosterom; J R Bänffer; S Lauwers; A E Busschbach
Journal:  Antonie Van Leeuwenhoek       Date:  1985       Impact factor: 2.271

8.  Guillain-Barré syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barré Study Group.

Authors:  L H Visser; F G Van der Meché; P A Van Doorn; J Meulstee; B C Jacobs; P G Oomes; R P Kleyweg; J Meulstee
Journal:  Brain       Date:  1995-08       Impact factor: 13.501

9.  Serum anti-GQ1b IgG antibodies recognize surface epitopes on Campylobacter jejuni from patients with Miller Fisher syndrome.

Authors:  B C Jacobs; H Endtz; F G van der Meché; M P Hazenberg; H A Achtereekte; P A van Doorn
Journal:  Ann Neurol       Date:  1995-02       Impact factor: 10.422

Review 10.  Campylobacter species and Guillain-Barré syndrome.

Authors:  I Nachamkin; B M Allos; T Ho
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

View more
  34 in total

1.  Identification of Campylobacter heat-stable and heat-labile antigens by combining the Penner and Lior serotyping schemes.

Authors:  David L Woodward; Frank G Rodgers
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

2.  Survival of Campylobacter jejuni in waterborne protozoa.

Authors:  W J Snelling; J P McKenna; D M Lecky; J S G Dooley
Journal:  Appl Environ Microbiol       Date:  2005-09       Impact factor: 4.792

3.  Structural and kinetic analysis of substrate binding to the sialyltransferase Cst-II from Campylobacter jejuni.

Authors:  Ho Jun Lee; Luke L Lairson; Jamie R Rich; Emilie Lameignere; Warren W Wakarchuk; Stephen G Withers; Natalie C J Strynadka
Journal:  J Biol Chem       Date:  2011-08-05       Impact factor: 5.157

4.  The crucial role of Campylobacter jejuni genes in anti-ganglioside antibody induction in Guillain-Barre syndrome.

Authors:  Peggy C R Godschalk; Astrid P Heikema; Michel Gilbert; Tomoko Komagamine; C Wim Ang; Jobine Glerum; Denis Brochu; Jianjun Li; Nobuhiro Yuki; Bart C Jacobs; Alex van Belkum; Hubert P Endtz
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

5.  Molecular evidence for dissemination of unique Campylobacter jejuni clones in Curaçao, Netherlands Antilles.

Authors:  Birgitta Duim; Peggy C R Godschalk; Nicole van den Braak; Kate E Dingle; Jeroen R Dijkstra; Ewald Leyde; Jan van der Plas; Frances M Colles; Hubert P Endtz; Jaap A Wagenaar; Martin C J Maiden; Alex van Belkum
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

6.  Risk factors associated with Campylobacter jejuni infections in Curaçao, Netherlands Antilles.

Authors:  Hubert P Endtz; Hanneke van West; Peggy C R Godschalk; Lidewij de Haan; Yaskara Halabi; Nicole van den Braak; Barbara I Kesztyüs; Ewald Leyde; Alewijn Ott; Roel Verkooyen; Lawrence J Price; David L Woodward; Frank G Rodgers; C Wim Ang; Rinske van Koningsveld; Alex van Belkum; Izzy Gerstenbluth
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

7.  Enteritis caused by Campylobacter jejuni followed by acute motor axonal neuropathy: a case report.

Authors:  Biljana Miljković-Selimović; Dragana Lavrnić; Olga Morić; Lai-King Ng; Lawrence Price; Ljubica Suturkova; Branislava Kocic; Tatjana Babić; Ljiljana Ristić; Slobodan Apostolski
Journal:  J Med Case Rep       Date:  2010-03-31

8.  Comparative population structure analysis of Campylobacter jejuni from human and poultry origin in Bangladesh.

Authors:  Z Islam; A van Belkum; J A Wagenaar; A J Cody; A G de Boer; S K Sarker; B C Jacobs; K A Talukder; H P Endtz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-06-26       Impact factor: 3.267

9.  Comparative genotyping of Campylobacter jejuni strains from patients with Guillain-Barré syndrome in Bangladesh.

Authors:  Zhahirul Islam; Alex van Belkum; Jaap A Wagenaar; Alison J Cody; Albert G de Boer; Helen Tabor; Bart C Jacobs; Kaisar A Talukder; Hubert P Endtz
Journal:  PLoS One       Date:  2009-09-30       Impact factor: 3.240

10.  Campylobacter jejuni HS:23 and Guillain-Barre syndrome, Bangladesh.

Authors:  Zhahirul Islam; Alex van Belkum; Alison J Cody; Helen Tabor; Bart C Jacobs; Kaisar A Talukder; Hubert P Endtz
Journal:  Emerg Infect Dis       Date:  2009-08       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.